Christopher Simon - 17 May 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
President & CEO, Director
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Simon
Issuer symbol
HAE
Transactions as of
17 May 2024
Transactions value $
-$386,462
Form type
4
Filing time
21 May 2024, 17:38:38 UTC
Previous filing
17 May 2024
Next filing
29 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Tax liability -$386K -4.04K -1.59% $95.73 250K 17 May 2024 Direct F1, F2
transaction HAE Common Stock Award +14.6K +5.84% 265K 17 May 2024 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +32.1K $0.00 32.1K 17 May 2024 Common Stock 32.1K $95.73 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2 This number includes unvested RSUs previously reported.
F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F5 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.